A new 15-minute tool to screen stroke survivors for visual perception problems has been launched by researchers from Durham and Oxford universities.
Risk Adjusted Net Present Value: What is the current valuation of Caribou Biosciences’s CB-012
Share this article The revenue for CB-012 is expected to reach an annual total of $11 mn by 2039 in the US based off GlobalData’s